Table 1 The table shows characteristics of individuals with light-chain monoclonal gammopathies included in flow cytometry analysis of plasma cells in bone marrow samples (Flow cytometry cohort) and individuals with kappa-involved light-chain monoclonal gammopathy of undetermined significance who were randomized for active follow-up within the iStopMM study (Follow-up cohort).
Characteristic | Flow cytometry cohort | Follow-up cohort |
|---|---|---|
n | 61 | 195 |
Age (range) | 67 (43–89) | 71 (43–92) |
Male sex, n (%) | 43 (70.5%) | 118 (60.5%) |
Kappa-involved FLC, n (%) | 42 (68.9%) | 195 (100%) |
FLC ratio, median (IQR) | 7.57 (2.85–29.0) | 2.07 (1.77–4.71) |
Lambda-involved FLC, n (%) | 19 (31.1%) | 0 |
FLC ratio, median (IQR) | 0.0560 (0.0253−0.107) | n.a. |
LC-MG screening resultsa, n (%) | ||
Standard LC-MGUS | 55 (90.2%) | 195 (100%) |
Revised LC-MGUS | 43 (70.5%) | 72 (36.9%) |
LC-MM | 6 (9.8%) | 0 (0.0%) |
Diagnosis at baselineb, n (%) | ||
LC-MGUS | 28 (45.9%) | 181 (92.8%) |
LC-SMM | 24 (39.3%) | 13 (6.7%) |
LC-MM | 8 (13.1%) | 0 (0.0%) |
SPM | 1 (1.6%) | 0 (0.0%) |
Chronic lymphocytic leukemia | 0 (0.0%) | 1 (0.5%) |
